G6PD (Quantitative) at Dr. Essa Lab

Introduction to G6PD (Quantitative) at Dr. Essa Lab

The Glucose-6-Phosphate Dehydrogenase (G6PD) Quantitative test is a highly specialized diagnostic laboratory investigation designed to measure the precise enzymatic activity of G6PD in red blood cells. G6PD is a vital cytosolic enzyme that plays a critical role in the pentose phosphate pathway, a metabolic pathway that supplies reducing energy to cells by maintaining the level of the coenzyme nicotinamide adenine dinucleotide phosphate (NADPH). In red blood cells, NADPH is uniquely essential because it keeps glutathione in its reduced state. Reduced glutathione acts as a primary antioxidant shield, neutralizing reactive oxygen species (ROS) and protecting the erythrocyte membrane and vital hemoglobin molecules from oxidative damage and premature destruction.

When an individual has a G6PD deficiency, their red blood cells are highly susceptible to oxidative stress. Under normal circumstances, deficient individuals may remain entirely asymptomatic. However, when exposed to specific triggers—such as certain infections, oxidative medications, or fava beans—the lack of sufficient G6PD enzyme activity prevents the regeneration of reduced glutathione. This leads to the rapid accumulation of free radicals, causing the oxidation of hemoglobin. The oxidized hemoglobin precipitates into distinct intracellular inclusions known as Heinz bodies. The presence of Heinz bodies damages the red blood cell membrane, leading to intravascular hemolysis and the splenic clearance of damaged cells (extravascular hemolysis), culminating in acute hemolytic anemia.

At Dr. Essa Lab, the G6PD Quantitative test is performed using state-of-the-art spectrophotometric kinetic assays. Unlike qualitative screening tests that merely indicate the presence or absence of the enzyme above a certain threshold, the quantitative assay provides an exact numerical value of enzyme activity per gram of hemoglobin (U/g Hb). This precise measurement is clinically invaluable for classifying the severity of the deficiency, managing pediatric patients presenting with neonatal jaundice, evaluating unexplained hemolytic episodes, and screening patients before initiating potentially hazardous oxidative therapies. By choosing Dr. Essa Lab, patients and clinicians across Karachi and Pakistan gain access to highly accurate, reproducible, and timely diagnostic insights backed by decades of laboratory excellence.

Clinical Procedure: What to Expect

Patient Preparation

Appropriate patient preparation is vital to ensure the clinical accuracy of the G6PD Quantitative test. Patients are advised to follow these guidelines closely:

• No Fasting Required: Fasting is generally not required for this test. Patients can eat and drink normally prior to sample collection.
• Timing of the Test: It is clinically critical to avoid performing this test during or immediately after an acute hemolytic episode. During hemolysis, older red blood cells (which contain the lowest levels of the G6PD enzyme) are destroyed first. The bone marrow responds by releasing young red blood cells (reticulocytes) into circulation. Reticulocytes naturally possess significantly higher levels of G6PD enzyme activity, which can temporarily mask a true deficiency and yield a false-normal result. It is recommended to wait at least 2 to 3 months after an acute hemolytic crisis before undergoing quantitative testing.
• Blood Transfusion History: If the patient has recently received a blood transfusion, the test must be postponed for at least 3 months. Transfused red blood cells from a donor with normal G6PD levels will contaminate the sample, leading to inaccurate, falsely elevated results.
• Medication Disclosure: Patients must inform the healthcare provider and laboratory staff of all medications, supplements, and herbal remedies they are currently taking, particularly those known to cause oxidative stress.

During the Procedure

The G6PD Quantitative test is a straightforward, minimally invasive blood test. The procedure at Dr. Essa Lab follows strict clinical protocols to ensure patient safety and sample integrity:

• Patient Identification and Verification: The phlebotomist will verify the patient’s identity using standard protocols and confirm compliance with preparation guidelines, particularly regarding recent transfusions or hemolytic episodes.
• Venipuncture Site Selection: The patient is seated comfortably. The phlebotomist typically selects a prominent vein in the antecubital fossa (the inner elbow area).
• Aseptic Technique: The skin over the selected vein is thoroughly cleansed with an antiseptic solution (such as 70% isopropyl alcohol) and allowed to air dry to prevent hemolysis of the sample.
• Sample Collection: A sterile, single-use needle is inserted into the vein, and blood is collected into an EDTA (purple-top) or heparinized (green-top) vacuum tube. The choice of anticoagulant is critical for maintaining erythrocyte viability during transport and analysis.
• Post-Collection Care: Once the required volume of blood is collected, the needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton swab to minimize hematoma formation. A small adhesive bandage is applied.
• Sample Mixing: The collection tube is gently inverted 8 to 10 times immediately after collection to ensure thorough mixing of the blood with the anticoagulant, preventing micro-clot formation.
• Procedure Duration: The entire phlebotomy process is completed within 5 to 10 minutes. The patient may experience a mild, brief pinching sensation as the needle enters the vein.

When is a G6PD (Quantitative) Performed?

Neonatal Jaundice Evaluation

Physicians frequently order a quantitative G6PD test for newborns who exhibit severe, prolonged, or atypical neonatal jaundice, particularly within the first 24 hours of life. In infants with G6PD deficiency, hyperbilirubinemia can escalate rapidly, posing a severe risk of bilirubin-induced neurological dysfunction (BIND) or kernicterus. Identifying a G6PD deficiency early allows pediatricians to implement aggressive phototherapy or exchange transfusions promptly, preventing irreversible neurological damage.

Unexplained Acute Hemolytic Anemia

When a patient presents with sudden clinical signs of hemolysis—such as acute fatigue, pallor, dark tea-colored urine, scleral icterus (yellowing of the eyes), and splenomegaly—clinicians utilize the G6PD Quantitative test to investigate the underlying cause. The test helps differentiate G6PD deficiency from other causes of hemolytic anemia, such as autoimmune hemolytic anemia, hereditary spherocytosis, or hemoglobinopathies, enabling targeted clinical management.

Prior to Administering Oxidant Medications

Before initiating treatment with medications known to trigger oxidative stress, physicians routinely screen patients for G6PD deficiency. Common culprit medications include antimalarials (such as primaquine and tafenoquine), sulfonamides (like sulfamethoxazole), dapsone, nitrofurantoin, and certain high-dose analgesics. Quantitative testing prior to therapy is a critical safety measure that prevents the accidental induction of life-threatening acute hemolytic crises.

Family History of G6PD Deficiency

Because G6PD deficiency is an X-linked recessive genetic disorder, it primarily affects males, while females are typically asymptomatic carriers. If a family has a known history of G6PD deficiency, clinical screening of male infants and quantitative assessment of female relatives (who may have intermediate enzyme levels due to lyonization/X-chromosome inactivation) is highly recommended for proactive dietary and lifestyle counseling.

Exposure to Oxidative Triggers

Physicians request this test when a patient develops symptoms of hemolytic anemia after consuming fava beans (a condition historically known as favism) or after inhaling pollen from the fava plant. It is also indicated following severe bacterial or viral infections, which are among the most common triggers of oxidative stress and subsequent hemolysis in G6PD-deficient individuals.

What Does a G6PD (Quantitative) Detect?

The G6PD Quantitative test is designed to detect, measure, and classify several critical clinical states and physiological parameters:

• Normal G6PD Enzyme Activity: Confirms that red blood cells possess adequate levels of the G6PD enzyme to withstand standard physiological and environmental oxidative challenges.
• Severe G6PD Deficiency (Class I): Identifies extremely low enzyme activity (often less than 10% of normal) associated with chronic nonspherocytic hemolytic anemia, even in the absence of external triggers.
• Moderate to Severe Deficiency (Class II): Detects significantly reduced enzyme levels (less than 10% of normal) typical of Mediterranean variants, which are highly susceptible to severe, acute hemolytic crises upon exposure to triggers.
• Moderate Deficiency (Class III): Identifies mild to moderate deficiency (10% to 60% of normal activity), commonly seen in the A- variant, where hemolysis is usually self-limiting as young red blood cells retain some enzyme activity.
• Asymptomatic Carrier Status in Females: Detects intermediate enzyme levels in heterozygous females. Due to random X-chromosome inactivation, carrier females can exhibit a wide range of G6PD activity, sometimes placing them at risk for mild to moderate hemolytic episodes.
• Risk of Drug-Induced Hemolysis: Quantifies the patient’s vulnerability to specific oxidative medications, allowing clinicians to safely select alternative therapeutic agents.
• Susceptibility to Favism: Determines whether a patient is at risk of developing severe, acute intravascular hemolysis upon dietary exposure to fava beans.
• Infection-Triggered Hemolytic Risk: Assesses the likelihood of a patient developing hemolytic anemia during acute infectious processes, such as diabetic ketoacidosis, hepatitis, or severe bacterial infections.
• Erythrocyte Metabolic Integrity: Evaluates the overall functional capacity of the hexose monophosphate shunt within the patient’s red blood cells.
• Source of Neonatal Hyperbilirubinemia: Pinpoints G6PD deficiency as the root cause of pathological jaundice in newborns, guiding immediate clinical intervention.
• False-Normal Masking: Helps clinicians recognize when high reticulocyte counts (following recent hemolysis) may have temporarily masked a deficiency, indicating the need for a follow-up test.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that timely diagnostic results are crucial for effective clinical decision-making and patient peace of mind. The G6PD Quantitative test is processed using fully automated, high-throughput clinical chemistry analyzers that undergo daily calibration and stringent quality control checks. Under standard operating conditions, the turnaround time for the G6PD Quantitative test report is typically within 24 to 48 hours from the time of sample collection.

Dr. Essa Lab provides highly convenient options for patients to access their diagnostic reports. Once the results are verified by our consultant pathologists, patients receive an automated SMS notification containing a direct link to download their report. Reports can also be accessed securely through the official Dr. Essa Lab website by entering the patient’s lab ID and password. For added convenience, physical copies of reports can be collected from any of our numerous collection centers across Karachi and other major cities, or delivered directly to patients via our dedicated home delivery services.

G6PD (Quantitative) Findings Overview

The following table outlines the typical parameters evaluated during a G6PD Quantitative test, along with general clinical interpretations of normal and abnormal findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
G6PD Enzyme Activity	Within established reference range (typically 7.0 – 20.5 U/g Hb, varying slightly by age and lab methodology)	Decreased levels (deficiency, classified from Class I to Class III); Falsely elevated levels during reticulocytosis
Hemoglobin (Hb) Level	Normal range (Male: 13.5–17.5 g/dL; Female: 12.0–15.5 g/dL)	Decreased levels indicating anemia, particularly acute drop during hemolytic crises
Reticulocyte Count	0.5% – 2.5% of total red blood cells	Elevated levels (reticulocytosis) indicating bone marrow response to active or recent hemolysis
Serum Bilirubin (Total & Indirect)	Total: 0.2 – 1.2 mg/dL; Indirect: < 0.8 mg/dL	Elevated indirect (unconjugated) bilirubin, reflecting rapid breakdown of red blood cells
Haptoglobin	30 – 200 mg/dL	Significantly decreased or undetectable levels, indicating active intravascular hemolysis
Lactate Dehydrogenase (LDH)	140 – 280 U/L	Markedly elevated levels, indicating acute cellular damage and red blood cell lysis
Peripheral Blood Smear	Normal red blood cell morphology (normocytic, normochromic)	Presence of Heinz bodies (with special stains), “bite cells,” “blister cells,” and polychromasia

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for G6PD (Quantitative)?

• Decades of Diagnostic Excellence: Established in 1987, Dr. Essa Lab is one of Pakistan’s most trusted diagnostic institutions, renowned for clinical accuracy and reliability.
• ISO Certified Quality Standards: Our laboratories operate under strict ISO 9001:2015 quality management systems, ensuring international standards of testing and reporting.
• Expert Pathologists: All quantitative assays are supervised and verified by highly qualified consultant pathologists and clinical biochemists.
• Advanced Automated Technology: We utilize state-of-the-art spectrophotometric analyzers that minimize human error and deliver precise quantitative measurements.
• Rigorous Quality Control: Our laboratory participates in robust internal and external quality assurance programs to maintain the highest level of diagnostic precision.
• Convenient Online Portal: Patients can easily download, view, and share their diagnostic reports online via our secure website or mobile application.
• Extensive Collection Network: With numerous branches and collection points across Karachi and Sindh, accessing professional diagnostic services is convenient and hassle-free.
• Compassionate Patient Care: Our dedicated phlebotomists and support staff are trained to provide a comfortable, safe, and professional experience for patients of all ages, including newborns and pediatric patients.